Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) has emerged as a significant adverse event associated with anticoagulant use, yet real-world data comparing the renal safety profiles of different anticoagulants remain limited. This study aims to evaluate the association between various anticoagulants and AKI, and to characterize the clinical features and outcomes of anticoagulant-associated AKI using the FDA Adverse Event Reporting System (FAERS).
We searched REAC files using MedDRA (v27.0) at the PT level for AKI-related terms like "acute kidney injury", "subacute kidney injury", "blood creatinine increased", "blood urea abnormal", "glomerular filtration rate decreased", "renal impairment", "oliguria", "anuria", "dialysis", "proteinuria", "renal tubular injury", "nephropathy toxic", "nephritis allergic", and "tubulointerstitial nephritis", primarily with anticoagulants. We applied disproportionality analysis (ROR, PRR) and Bayesian analysis (BCPNN, MGPS) to analyze AKI reports linked to anticoagulants in FAERS from 2004Q1 to 2025Q1. We investigated demographic characteristics, temporal patterns, and outcomes, with statistical significance at P<0.05 and 95% CIs. Analyses used R v4.3.2.
This study analyzed FAERS data from 2004-2025. After screening 22,775,812 reports and removing duplicates per FDA recommendations, 19,026,509 reports were analyzed (Fig. A).
Warfarin had stable low reports, while newer oral anticoagulants (NOACs) showed dramatic trends: Apixaban peaked over 20,000 around 2021, Rivaroxaban near 20,000 in 2015, Dabigatran over 11,000 in 2012. Drugs like Argatroban, Bivalirudin, and Dalteparin had consistently low reports (Fig. B).
12,105 anticoagulant-associated AKI cases were identified, mostly in patients ≥65 years (65.37%). Lepirudin had the strongest AKI association (ROR=4.51, 95%CI=2.74-7.42). AmongDOACs, dabigatran showedhighest risk (ROR=2.69, 95%CI=2.59-2.79), apixaban the weakest (ROR=1.26,95%CI=1.21-1.32).( Median AKI onset was 36 days, with 47.9% in the first month. Fatality rate was 22.75%, highest with bivalirudin (56.25%) (Fig. C,D).
Fig. E uses RORwith 95% CIto measure associations between anticoagulants and re研究抗凝药物与……之间的关联关系。nal ADRs. Fondaparinux, Apixaban, Dabigatran, and Bi奥丹帕利oux、阿哌沙班、达比加群……valirudin show high RORs for specific renal ADRs like Dialysis and Blood Urea Increased. Conversely, Warfarin and others have near-zero RORs for ADRs such as Acute Kidney Injury.针对急性肾损伤等急性疾病反应的RORs。
Conclusion:
Anticoagulants vary in AKI risk, with lepirudin and dabigatran posing highest risk. Monitor renal function closely, especially in first month of treatment. Further studies needed to validate findings and identify patient-specific risk factors. Results show heterogeneity in renal ADRs; Fondaparinux and Apixaban signal specific toxicities. Findings can guide pharmacovigilance and clinical decisions for renal risk patients.
